Post-approval studies (Phase 4)Ended earlyNCT01131325
What this trial is testing
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
Who this might be right for
CMLPhiladelphia Chromosome Positive (Ph+)Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Novartis Pharmaceuticals 3